HC Wainwright Has Negative Estimate for STOK FY2026 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued on Monday, November 2nd. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($3.93) per share for the year, down from their prior estimate of ($3.35). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($3.58) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2026 earnings at ($1.11) EPS, Q1 2027 earnings at ($1.10) EPS, Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($0.90) EPS, Q4 2027 earnings at ($0.85) EPS, FY2027 earnings at ($3.98) EPS and FY2028 earnings at ($1.74) EPS.

A number of other brokerages have also recently commented on STOK. Wedbush upped their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.17.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $26.99 on Wednesday. The business has a 50-day moving average price of $27.21 and a 200 day moving average price of $30.85. Stoke Therapeutics has a 52-week low of $20.32 and a 52-week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). The firm had revenue of $11.26 million during the quarter, compared to analyst estimates of $8.21 million. Stoke Therapeutics had a negative net margin of 862.07% and a negative return on equity of 66.76%.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. raised its position in shares of Stoke Therapeutics by 35.7% in the third quarter. Alps Advisors Inc. now owns 85,483 shares of the company’s stock valued at $2,223,000 after buying an additional 22,473 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Stoke Therapeutics during the third quarter worth approximately $86,000. China Universal Asset Management Co. Ltd. boosted its position in Stoke Therapeutics by 29.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,054 shares of the company’s stock worth $338,000 after acquiring an additional 2,942 shares during the last quarter. SYM FINANCIAL Corp purchased a new stake in Stoke Therapeutics in the 3rd quarter worth approximately $1,562,000. Finally, Sterling Capital Management LLC grew its stake in Stoke Therapeutics by 849.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,833 shares of the company’s stock worth $48,000 after acquiring an additional 1,640 shares during the period.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 5,545 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total value of $170,065.15. Following the completion of the transaction, the insider directly owned 20,110 shares of the company’s stock, valued at approximately $616,773.70. This trade represents a 21.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 2,861 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $91,637.83. Following the sale, the general counsel owned 21,225 shares of the company’s stock, valued at approximately $679,836.75. The trade was a 11.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 27,418 shares of company stock worth $860,914. 9.60% of the stock is owned by company insiders.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2028 EPS forecast slightly, to a loss of $1.74 per share from a loss of $1.78. MarketBeat
• Neutral Sentiment: Stoke announced upcoming investor-conference presentations in November; the notice provides no specific new financial or clinical information. Conference announcement
• Neutral Sentiment: The company’s Q3 2026 earnings-call presentation was posted, but the supplied article entry does not include details that indicate a fresh market-moving development. Q3 results presentation
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a loss of $3.93 from $3.35 and its FY2027 estimate to a loss of $3.98 from $2.55. It also lowered its Q4 2026 forecast to a loss of $1.11 per share from $0.81, implying greater expected losses and potentially weighing on sentiment. MarketBeat
• Negative Sentiment: The analyst also trimmed long-term estimates for FY2029 EPS to $1.51 from $1.55 and FY2030 EPS to $3.48 from $3.56, tempering the longer-term earnings outlook. MarketBeat

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.